Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
